Lilly (Eli) (LLY)

Total Costs & Expenses

$40.06B

TTM · Period ending: · USD

LLY logo

LLY Total Costs & Expenses

Latest reported$40.06B
LLY TTM Total Costs & Expenses ($2.86B → $40.06B)
High-resolution chart · PNG

LLY total costs & expenses history

Trailing twelve months (TTM) · USD. Each value covers four complete reported quarters.

Lilly (Eli) Total Costs & Expenses — Trailing twelve months (TTM) (USD)
Period endingTotal Costs & Expenses (USD)
40,057,300,000
38,077,300,000
35,483,300,000
33,029,500,000
30,819,500,000
29,166,800,000
27,772,200,000
26,081,700,000
25,034,600,000
24,124,000,000
23,336,800,000
22,270,800,000
21,217,000,000
19,986,500,000
19,888,100,000
20,322,800,000
20,060,400,000
20,540,000,000
20,446,500,000
19,971,900,000
19,577,400,000
18,379,500,000
17,438,400,000
16,894,100,000
16,563,200,000
16,601,900,000
16,320,100,000
16,651,100,000
16,563,600,000
16,436,100,000
16,160,500,000
16,711,600,000
17,324,100,000
17,897,900,000
18,453,800,000
17,768,300,000
17,530,000,000
17,443,600,000
17,350,800,000
17,275,900,000
17,029,200,000
16,629,000,000
16,366,600,000
15,973,500,000
16,199,800,000
16,225,500,000
16,286,900,000
16,863,700,000
16,909,300,000
17,223,500,000
17,565,000,000
17,438,400,000
17,514,300,000
17,549,600,000
17,588,100,000
17,709,600,000
17,942,600,000
18,075,700,000
17,968,600,000
17,817,200,000
17,182,700,000
16,617,600,000
16,303,800,000
16,246,100,000
16,219,600,000
15,949,100,000
15,466,000,000
14,559,900,000
14,441,500,000
14,598,000,000
14,844,000,000
15,131,000,000
14,750,500,000
14,276,000,000
13,830,600,000
13,036,200,000
12,473,600,000
11,968,900,000
11,565,600,000
11,275,500,000
11,128,800,000
11,035,300,000
10,996,700,000
10,768,400,000
10,517,600,000
10,388,600,000
10,199,200,000
10,105,500,000
9,899,500,000
9,477,500,000
9,080,700,000
8,567,900,000
8,248,200,000
8,005,000,000
7,749,800,000
7,726,200,000
7,816,000,000
7,816,200,000
7,812,700,000
7,828,000,000
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.